A randomized, crossover, open label pilot study to evaluate the efficacy and safety of Xalatan in comparison with generic Latanoprost (Latoprost) in subjects with primary open angle glaucoma or ocular hypertension

Narayanaswamy, Arun; Neog, Aditya; Baskaran, M.; George, Ronnie; Lingam, Vijaya; Desai, Chetan; Rajadhyaksha, Viraj
March 2007
Indian Journal of Ophthalmology;Mar2007, Vol. 55 Issue 2, p127
Academic Journal
journal article
Aim: To compare the efficacy and tolerability of Xalatan with generic latanoprost (Latoprost) in subjects with primary open angle glaucoma (POAG) or ocular hypertension (OH).Materials and Methods: This was a single-center, randomized, open label, crossover, two period comparative study. At the baseline visit, subjects were randomized to two groups. Group A received Xalatan for weeks 1-12 followed by Latoprost for weeks 13-24. Group B received Latoprost for weeks 1-12 followed by Xalatan for weeks 13-24.Results: 30 subjects were recruited, 12 in Group A and 18 in Group B. In subjects administered Xalatan, intraocular pressure (IOP) showed a greater decrease (P < 0.001) from 23.64 +/- 3.13 mmHg at baseline to 14.29 +/- 1.61 mmHg at week 12 (fall of 9.35 +/- 3.55 mmHg, 38.66% +/- 10.29) than that seen in the Latoprost group (22.74 +/- 2.47 mmHg to 16.98 +/- 2.49 mmHg, fall of 5.76 +/- 1.41 mmHg; 25.42% +/- 5.98). In period 2 when subjects were crossed over to Xalatan from Latoprost, there was a further fall from 16.98 +/- 2.49 mmHg to 16.09 +/- 1.49 at week 24 (fall of 0.89 +/- 1.59 mmHg; 4.3% +/- 8.76). However, when subjects were crossed over to Latoprost from Xalatan, the IOP rose from 14.29 +/- 1.61 mmHg to 15.36 +/- 1.71 mmHg at week 24 (8.86% +/- 17.76). There was no significant difference in incidence of conjunctival hyperemia or any other adverse events in both the groups.Conclusion: The magnitude of IOP lowering in patients with POAG and OH with Xalatan and Latoprost is different. In our study, the IOP lowering with Xalatan was higher than that with Latoprost.


Related Articles

  • Punctal plug delivery system shows good safety, efficacy.  // Primary Care Optometry News;Dec2012, Vol. 17 Issue 12, p7 

    The article highlights findings of a study which evaluated the safety and efficacy of a punctal plug delivery system with latanoprost when used in subjects with ocular hypertension or open-angle glaucoma.

  • Xalatan.  // Royal Society of Medicine: Medicines;2002, p571 

    This article provides information on Xalatan, a proprietary, prescription-only preparation of the prostaglandin analogue latanoprost. It can be used as a glaucoma treatment in open-angle glaucoma and ocular hypertension. It is available as eye-drops.

  • Days of IOP control help determine drug effectiveness. Zimmerman, Thom J. // Ophthalmology Times;1/15/2007, Vol. 32 Issue 2, p43 

    The article evaluates the drug latanoprost (Xalatan), prescribed for patients undergoing treatment for primary open-angle glaucoma, which is manufactured by Pfizer Inc.

  • OHTS Guide: The Clinical Findings.  // Review of Optometry;12/15/2002, Vol. 139 Issue 12, p44 

    Examines the efficacy of he Ocular Hypertension Treatment Study (OHTS) in assisting clinicians on treatment decisions for ocular hypertension. Functions of the OHTS and evaluating the safety and efficacy of topical ocular hypotensive medication; Aims in preventing the development of primary...

  • Preservative-Free Latanoprost Eye Drops in Patients with Primary Open-Angle Glaucoma/Ocular Hypertension. Sanford, Mark // Clinical Drug Investigation;Jul2014, Vol. 34 Issue 7, p521 

    Latanoprost is an ester prodrug prostaglandin F analogue that is a selective agonist of endogenous prostanoid FP receptors and that reduces intraocular pressure (IOP) by increasing the uveoscleral outflow of aqueous humour. Preservative-free (PF) latanoprost [Monoprost] is a new formulation of...

  • HLA-DR Expression in Conjunctival Cells After Latanoprost. Guglielminetti, Elena; Barabino, Stefano; Monaco, Marina; Mantero, Stefano; Rolando, Maurizio // Journal of Ocular Pharmacology & Therapeutics;Feb2002, Vol. 18 Issue 1, p1 

    The purpose of this randomized, controlled, masked study was to evaluate the effects of latanoprost 0.005% (Xalatan[sup ®], Pharmacia and Upjohn, Milan, Italy) on the ocular surface in patients with ocular hypertension or primary open-angle glaucoma. The study group included 14 patients who...

  • Efficacy and safety of the latanoprost/timolol maleate fixed combination vs concomitant brimonidine and latanoprost therapy. Stewart, W. C.; Stewart, J. A.; Day, D. G.; Sharpe, E. D.; Jenkins, J. N. // Eye;Oct2004, Vol. 18 Issue 10, p990 

    AIMS:To evaluate the efficacy and safety of latanoprost/timolol maleate fixed combination (LTFC) given once daily vs the concomitant therapy of brimonidine twice daily and latanoprost once daily in primary open-angle glaucoma or ocular hypertensive subjects. METHODS:A prospective, double-masked,...

  • Phase 2 trials demonstrate efficacy of punctal plug in lowering IOP.  // Primary Care Optometry News;Dec2012, Vol. 17 Issue 12, p18 

    The article highlights two multi center phase 2 clinical trials which demonstrated the safety and efficacy of Latanoprost Punctal Plug Delivery System from QLT in patients with ocular hypertension and open-angle glaucoma.

  • The Use of Latanoprost 0.005% Once Daily and its Effect on Intraocular Pressure as Primary or Adjunctive Therapy. Smith, Shannon L.; Stewart, William C.; Sine, Cheryl S.; Pruitt, Caroline A. // Journal of Ocular Pharmacology & Therapeutics;Feb99, Vol. 15 Issue 1, p29 

    Presents a study which evaluated differences in efficacy and safety of latanoprost as monotherapy compared to adjunctive therapy in primary open-angle glaucoma. Materials and methods; Results; Discussion.


Read the Article

Courtesy of

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics